NASDAQ:VBLT
Delisted
Vascular Biogenics Ltd. Stock News
$0.156
+0 (+0%)
At Close: Jan 12, 2024
Why PagSeguro Digital Shares Are Trading Lower By 18%? Here Are 40 Stocks Moving In Wednesday's Mid-Day Session
06:27pm, Wednesday, 23'rd Nov 2022 Benzinga
Gainers
Cosmos Holdings Inc. (NASDAQ: COSM) rose 68% to $0.5500 after surging around 87% on Tuesday. Cosmos Holdings recently posted a Q3 loss of $0.08 per share.
COMSovereign Holding Corp. (NASDAQ:
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
12:55am, Tuesday, 15'th Nov 2022 Zacks Investment Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
VBL Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
09:05pm, Monday, 14'th Nov 2022 GlobeNewswire Inc.
Continued progress on previously announced strategic process to maximize shareholder value Continued progress on previously announced strategic process to maximize shareholder value
Vascular Biogenics (VBLT) Reports Q3 Loss, Tops Revenue Estimates
09:03pm, Monday, 14'th Nov 2022
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of -9.09% and 220.67%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock
Biofrontera Inc. (BFRI) Reports Q3 Loss, Tops Revenue Estimates
03:05pm, Monday, 14'th Nov 2022 Zacks Investment Research
Biofrontera Inc. (BFRI) delivered earnings and revenue surprises of 28.13% and 0.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
OYSTER PT PHARM (OYST) Reports Q3 Loss, Lags Revenue Estimates
10:35pm, Thursday, 10'th Nov 2022 Zacks Investment Research
OYSTER PT PHARM (OYST) delivered earnings and revenue surprises of 9.87% and 24.50%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Inhibrx, Inc. (INBX) Reports Q3 Loss, Misses Revenue Estimates
10:55pm, Monday, 07'th Nov 2022 Zacks Investment Research
Inhibrx, Inc. (INBX) delivered earnings and revenue surprises of 10.89% and 60.29%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Axsome (AXSM) Starts Late-Stage Study of Migraine Drug AXS-07
04:36pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Axsome (AXSM) initiates a phase III open-label study for its pipeline candidate, AXS-07 for treating acute migraine.
Pliant (PLRX) Receives Positive Review of IPF Study at Top Dose
04:29pm, Friday, 02'nd Sep 2022 Zacks Investment Research
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
VBL Therapeutics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
08:30pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
TEL AVIV, Israel and NEW YORK, Sept. 01, 2022 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (“VBL”), a biotechnology company developing targeted medicines for immune-inflammatory diseases,
Sorrento (SRNE) Gets FDA Fast Track Tag for Back Pain Product
04:45pm, Thursday, 01'st Sep 2022 Zacks Investment Research
Sorrento Therapeutics' (SRNE) subsidiary Scilex receives Fast Track designation for its lower back pain (LBP) candidate, SP-103. Stock Up.
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
09:35pm, Monday, 15'th Aug 2022 Zacks Investment Research
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vascular Biogenics (VBLT) Reports Q2 Loss, Misses Revenue Estimates
06:48pm, Monday, 15'th Aug 2022
Vascular Biogenics (VBLT) delivered earnings and revenue surprises of 7.69% and 57.33%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Rapt Therapeutics (RAPT) Reports Q2 Loss, Tops Revenue Estimates
01:15pm, Thursday, 11'th Aug 2022 Zacks Investment Research
Rapt Therapeutics (RAPT) delivered earnings and revenue surprises of 17.33% and 121.50%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Vir Biotechnology, Inc. (VIR) Reports Q2 Loss, Misses Revenue Estimates
10:05pm, Tuesday, 09'th Aug 2022 Zacks Investment Research
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -241.18% and 129.79%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stoc
